PACLITAXEL,HUMAN ALBUMIN
Background and Date of Approval
Paclitaxel combined with human albumin is a chemotherapeutic formulation approved to treat breast cancer, lung cancer, and pancreatic cancer. This combination uses albumin, a naturally occurring protein, to improve the solubility and delivery of paclitaxel to cancer cells while reducing toxicities associated with conventional solvents. The U.S. Food and Drug Administration approved this formulation in January 2005, following clinical trials that demonstrated its improved safety profile and efficacy. By utilising albumin-bound nanoparticles, this treatment provides an option for patients with improved tolerability and effectiveness compared to conventional paclitaxel formulations.
Uses
Paclitaxel, Human Albumin, is FDA-approved for the treatment of: Metastatic breast cancer. Non-small cell lung cancer (in combination with carboplatin). Metastatic pancreatic cancer (in combination with gemcitabine).
How is it administered?
This medication is administered as an intravenous infusion under medical supervision. The dosage varies depending on the type and severity of the cancer and the patientâs overall condition. Commonly available dosages include: 100 mg/vial 250 mg/vial Treatment is typically repeated every three weeks, with adjustments made based on the patientâs response and tolerance.
Side Effects
Common Side Effects Fatigue and weakness Hair loss (alopecia) Nausea and vomiting Joint and muscle pain Diarrhea Serious Side Effects Severe neutropenia (low white blood cell count) Peripheral neuropathy (tingling or numbness in extremities) Allergic reactions (rash, difficulty breathing) Pulmonary toxicity Cardiovascular complications such as low blood pressure
Warnings
Severe hypersensitivity reactions : Avoid in patients with prior severe allergic reactions to paclitaxel or albumin. Myelosuppression : Can lead to dangerously low white blood cell counts and infections. Peripheral neuropathy : High risk of nerve damage, requiring monitoring for symptoms. Liver impairment : Requires dosage adjustments in patients with hepatic dysfunction. Pregnancy and lactation : Not recommended due to potential harm to the fetus or nursing infant.
Precautions
Patients should inform their healthcare provider about existing medical conditions, especially liver disease, low blood counts, or neuropathy. Regular blood tests are essential to monitor the impact of treatment. It is crucial to avoid grapefruit or grapefruit juice as they may interfere with drug metabolism. Women of childbearing age should use effective contraception during and after treatment to prevent pregnancy-related risks. Maintaining hydration and reporting any unusual symptoms, such as fever or unusual bleeding, are critical during therapy.
Word of Advice
This medication must be given in a clinical setting under the supervision of trained healthcare professionals. Patients should follow the prescribed treatment schedule and promptly inform their doctor about any persistent or serious side effects, including unusual bruising or symptoms of infection. Maintaining a balanced diet and drinking adequate fluids may help alleviate certain side effects. Patients should also consult their doctor before taking any over-the-counter medicines, herbal supplements, or making major dietary changes, as these could interfere with the treatment.
References
Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond). 2007 Aug;2(4):415-23. doi: 10.2217/17435889.2.4.415. PMID: 17716129. https://pubmed.ncbi.nlm.nih.gov/17716129/ https://pubs.rsc.org/en/content/articlelanding/2014/md/c4md00200h https://www.cancer.gov/publications/dictionaries/cancer-terms/def/paclitaxel-albumin-stabilized-nanoparticle-formulation
Frequently Asked Questions
What is Paclitaxel, Human Albumin used for?
This medication is primarily used to treat metastatic breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer. It works by targeting rapidly dividing cancer cells and inhibiting their growth. The formulation combines paclitaxel with human albumin to improve drug delivery and reduce side effects. It offers an alternative for patients who cannot tolerate traditional solvent-based paclitaxel.
How is Paclitaxel, Human Albumin administered?
The drug is administered as an intravenous infusion under the supervision of a healthcare provider. The frequency of administration depends on the type of cancer being treated, but it is often given every three weeks. The infusion typically takes about 30 minutes to an hour. Dosage adjustments may be necessary based on the patientâs overall health and response to the treatment.
What are the common side effects of this treatment?
Common side effects include fatigue, nausea, hair loss, and joint or muscle pain. Patients may also experience mild diarrhoea or skin reactions. These side effects are generally manageable and temporary. It is important to notify your healthcare provider if side effects become severe or persistent.
Can Paclitaxel, Human Albumin affect fertility?
Yes, this medication may have an impact on fertility in both men and women. Women of childbearing age are advised to use effective contraception during and after the treatment period. Men should also discuss fertility preservation options with their doctor before starting therapy. Fertility typically recovers after treatment, but this depends on the individual case.
Should I avoid certain foods or medications during treatment?
Avoid grapefruit and grapefruit juice during treatment as they can interfere with the drugâs metabolism. Inform your doctor about all medications and supplements you are taking, as some may interact with the therapy. Maintaining a balanced diet can help manage side effects and support overall health during treatment. Always consult your healthcare provider before making any dietary or medication changes.